Literature DB >> 28121042

Economic case for intraoperative interventions to prevent surgical-site infection.

B M Gillespie1,2,3, W Chaboyer3, A Erichsen-Andersson4, R M Hettiarachchi5, S Kularatna5.   

Abstract

BACKGROUND: Surgical-site infection (SSI) occurs in 1-10 per cent of all patients undergoing surgery; rates can be higher depending on the type of surgery. The aim of this review was to establish whether (or not) surgical hand asepsis, intraoperative skin antisepsis and selected surgical dressings are cost-effective in SSI prevention, and to examine the quality of reporting.
METHODS: The authors searched MEDLINE via Ovid, CINAHL via EBSCO, Cochrane Central and Scopus databases systematically from 1990 to 2016. Included were RCTs and quasi-experimental studies published in English, evaluating the economic impact of interventions to prevent SSI relative to surgical hand and skin antisepsis, and wound dressings. Characteristics and results of included studies were extracted using a standard data collection tool. Study and reporting quality were assessed using SIGN and CHEERS checklists.
RESULTS: Across the three areas of SSI prevention, the combined searches identified 1214 articles. Of these, five health economic studies evaluating the cost-effectiveness of selected surgical dressings were eligible. Study authors concluded that the interventions being assessed were cost-effective, or were potentially cost-saving. Still, there is high uncertainty around the decision to adopt these dressings/devices in practice. The studies' reporting quality was reasonable; three reported at least 15 of the 24 CHEERS items appropriately. Assessment of methodological quality found that two studies were considered to be of high quality.
CONCLUSION: With few economic studies undertaken in this area, the cost-effectiveness of these strategies is unclear. Incorporating economic evaluations alongside RCTs will help towards evidence-informed decisions.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28121042     DOI: 10.1002/bjs.10428

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

1.  Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery.

Authors:  Maria B Schiavone; Lea Moukarzel; Kam Leong; Qin C Zhou; Anoushka M Afonso; Alexia Iasonos; Kara Long Roche; Mario M Leitao; Dennis S Chi; Nadeem R Abu-Rustum; Oliver Zivanovic
Journal:  Gynecol Oncol       Date:  2017-07-19       Impact factor: 5.482

2.  Therapeutic evaluation of immunomodulators in reducing surgical wound infection.

Authors:  Foyez Mahmud; Ruchi Roy; Mohamed F Mohamed; Anahita Aboonabi; Mario Moric; Kamran Ghoreishi; Mohammad Bayat; Timothy M Kuzel; Jochen Reiser; Sasha H Shafikhani
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

3.  Steroids in cardiac surgery trial: a substudy of surgical site infections.

Authors:  Graham R McClure; Emilie P Belley-Cote; John Harlock; Andre Lamy; Michael Stacey; P J Devereaux; Richard P Whitlock
Journal:  Can J Anaesth       Date:  2018-12-10       Impact factor: 5.063

4.  Quality appraisal of clinical guidelines for surgical site infection prevention: A systematic review.

Authors:  Brigid M Gillespie; Claudia Bull; Rachel Walker; Frances Lin; Shelley Roberts; Wendy Chaboyer
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

Review 5.  Systematic review of the cost-effectiveness of preoperative antibiotic prophylaxis in reducing surgical-site infection.

Authors:  J Allen; M David; J L Veerman
Journal:  BJS Open       Date:  2018-04-14

6.  Delphi prioritization and development of global surgery guidelines for the prevention of surgical-site infection.

Authors: 
Journal:  Br J Surg       Date:  2020-03-24       Impact factor: 6.939

7.  Surgical hand antisepsis: experimental study.

Authors:  Aldo Izaguirre; Arantza Govela; Ismael Delgado; Carlos Mateos Troncoso; María Parra; Enrique Álvarez Viaña
Journal:  Ann Surg Treat Res       Date:  2018-06-26       Impact factor: 1.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.